SNB
VNDA icon

Security National Bank’s Vanda Pharmaceuticals VNDA Stock Holding History

Security National Bank’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-148
Closed -$625 – 322
2023
Q4 		$625 Buy
+148
New +$597 ﹤0.01% 298

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Security National Bank's VNDA Position: Q1 2024 in Review

Security National Bank sold out of Vanda Pharmaceuticals (VNDA) in Q1 2024, closing a stake of 148 shares — an estimated $625 sold.

Security National Bank first reported a position in VNDA in Q4 2023 and held it in 1 quarter. The position peaked at $625 in Q4 2023. 144 funds tracked by Wall St. Rank hold VNDA as of Q1 2024.

  • Security National Bank reported no remaining Vanda Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Security National Bank sold 148 Vanda Pharmaceuticals shares in Q1 2024, an estimated $625.
  • Security National Bank first reported a position in Vanda Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Security National Bank's Vanda Pharmaceuticals position peaked at $625 in Q4 2023.
  • 144 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2024.

Based on Security National Bank's 13F filing for Q1 2024, filed 15 Apr 2024.